Investors Overview

Corporate Profile

Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America.

Recent News
Mar 20, 2018

Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of...

Feb 28, 2018

90% increase in revenue and 214% increase in income from continuing operations for Q4 2017 Canadian launch of OZANEX™ in Jan 2018 Acquired Canadian rights to TRULANCE® in Feb 2018 MISSISSAUGA, ON,

Feb 28, 2018

A new differentiated treatment option for GI disorders Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market where innovative treatments are needed...